Benign Eyelid Research Articles

Population-Based Incidence and Clinical Characteristics of Ocular Adnexal Tumors in Olmsted County, Minnesota

ABSTRACT Purpose To determine the incidence and clinical characteristics of ocular adnexaltumors in Olmsted County, Minnesota. Methods Retrospective population-based cohort study of all patients residing in Olmsted County, Minnesota diagnosed with any ocular tumor from January 1, 2006, to December 31, 2015. The medical records of all patients with an incident diagnosis of any ocular adnexal tumor were reviewed using the Rochester Epidemiology Project medical record linkage system for patient demographics, tumor type, and histopathologic confirmation. Incidence rates were calculated per 100,000 person-years. Poisson regression analysis was used to analyze changes in incidence over time. Results There were 717 patients diagnosed with ocular adnexal tumors during the 10-year study period, yielding an age- and sex-adjusted incidence rate of 59.7 per 100,000 (95% CI 55.4 to 64.0, p < 0.05) per year. In total, 764 tumors were diagnosed. Most tumors were eyelid lesions (N = 756, 99.0%), which were mostly benign (N = 512, 67.8%) with epidermal inclusion cysts (N = 275, 36.0%), hidrocystoma (N = 70, 9.2%), and eyelid sebaceous cysts (N = 46, 6.1%) accounting for the majority. Malignant eyelid lesions (N = 244, 31.9%) were relatively common with basal cell carcinoma (N = 184, 24.1%) and squamous cell carcinoma (N = 49, 6.4%) having the highest frequencies. Orbital tumors (N = 8, 1.0%) were infrequent. Of the orbital tumors, the most common was lacrimal gland adenoidcystic carcinoma (N = 2, 25.0%). Conclusions In a population-based setting, most ocular adnexal tumors were benign eyelid lesions. Understanding the epidemiology of ocular adnexal tumors is important to aid providers in diagnosing and facilitating appropriate referrals of potentially vision- and life-threatening malignancies.

Computer-aided diagnosis of eyelid skin tumors using machine learning

ObjectiveTo develop an automated, new framework based on machine learning to diagnose malignant eyelid skin tumors. MethodsThis study used eyelid lesion images from Sheba Medical Center, a large tertiary center in Israel. Before model training, we pretrained our models on the International Skin Imaging Collaboration (ISIC) 2019 dataset consisting of 25,332 images. The proprietary eyelid data set was then used for fine-tuning. The data set contained multiple images per patient, aiming to classify malignant lesions in comparison to benign counterparts. ResultsThe analyzed data set consisted of images representing both benign and malignant eyelid lesions. For the benign category, a total of 373 images were sourced. By comparison, for the malignant category, 186 images were sourced. For the final model, at sensitivity of 93.8% (95% CI 80.0–100.0%), the model has a corresponding specificity of 73.7% (95% CI 60.0–87.1%). To further understand the decision-making process of our model, we employed heatmap visualization techniques, specifically gradient-weighted Class Activation Mapping. DiscussionThis study introduces a dependable model-aided diagnostic technology for assessing eyelid skin lesions. The model demonstrated accuracy comparable to human evaluation, effectively determining whether a lesion raises a high suspicion of malignancy or is benign. Such a model has the potential to alleviate the burden on the health care system, particularly benefiting rural areas, and enhancing the efficiency of clinicians and overall health care.

HM_ADET: a hybrid model for automatic detection of eyelid tumors based on photographic images

BackgroundThe accurate detection of eyelid tumors is essential for effective treatment, but it can be challenging due to small and unevenly distributed lesions surrounded by irrelevant noise. Moreover, early symptoms of eyelid tumors are atypical, and some categories of eyelid tumors exhibit similar color and texture features, making it difficult to distinguish between benign and malignant eyelid tumors, particularly for ophthalmologists with limited clinical experience.MethodsWe propose a hybrid model, HM_ADET, for automatic detection of eyelid tumors, including YOLOv7_CNFG to locate eyelid tumors and vision transformer (ViT) to classify benign and malignant eyelid tumors. First, the ConvNeXt module with an inverted bottleneck layer in the backbone of YOLOv7_CNFG is employed to prevent information loss of small eyelid tumors. Then, the flexible rectified linear unit (FReLU) is applied to capture multi-scale features such as texture, edge, and shape, thereby improving the localization accuracy of eyelid tumors. In addition, considering the geometric center and area difference between the predicted box (PB) and the ground truth box (GT), the GIoU_loss was utilized to handle cases of eyelid tumors with varying shapes and irregular boundaries. Finally, the multi-head attention (MHA) module is applied in ViT to extract discriminative features of eyelid tumors for benign and malignant classification.ResultsExperimental results demonstrate that the HM_ADET model achieves excellent performance in the detection of eyelid tumors. In specific, YOLOv7_CNFG outperforms YOLOv7, with AP increasing from 0.763 to 0.893 on the internal test set and from 0.647 to 0.765 on the external test set. ViT achieves AUCs of 0.945 (95% CI 0.894-0.981) and 0.915 (95% CI 0.860-0.955) for the classification of benign and malignant tumors on the internal and external test sets, respectively.ConclusionsOur study provides a promising strategy for the automatic diagnosis of eyelid tumors, which could potentially improve patient outcomes and reduce healthcare costs.

Plasma Exeresis for the Treatment of Benign Eyelid Lesions: A New Surgical Approach.

To report the plasma therapy technique and its clinical outcomes in patients with benign eyelid lesions. This is a retrospective, noncomparative, interventional study. The study included 71 eyes of 66 patients who underwent plasma exeresis for benign eyelid lesions in our clinic between February 2018 and December 2022. Patient symptoms, cosmetic outcomes, and complications were evaluated. The lesions were removed with a single plasma exeresis treatment in all patients. The mean size of the lesion at its largest part was 5.5 ± 1.2 mm (range, 3.0-8.8 mm). No complications were encountered during the procedure. The mean procedure time was 4.0 ± 0.7 minutes (range, 3-6 minutes). Postoperatively, only 3 cases (4.2%) with tarsal conjunctival extension had mild irritation symptoms such as pain, discomfort, and redness. The treated areas were fully improved cosmetically, and all patients were satisfied with the cosmetic outcomes. The plasma therapy technique for removing benign eyelid lesions offers minimally invasive surgery, less discomfort, fast recovery, and successful anatomical and cosmetic outcomes.

Eyelid Tumors at Razi and Farabi Hospitals, Tehran, Iran

Background: Eyelid tumors are common in the daily practice of skin tumors and are composed of benign and malignant lesions. Methods: This retrospective case series study collected histopathologic reports of eyelid tumors of patients treated between 2022 and 2023 in Razi and Farabi hospitals (Tehran, Iran). Patient data, including patient age, sex, location of the lesion, and recurrence, were collected. Descriptive and inferential statistics were used to characterize the subgroups. Results: The sample was composed of 154 eyelid tumor specimens, including 72 (47%) malignant cases, 80 (52%) benign cases, and 2 (1%) premalignant cases. Malignant tumors included 81.9% basal cell carcinomas (BCC), 15.3% basosquamous cell carcinomas (BSC), and 1.4% squamous cell carcinoma (SCC). The benign eyelid lesions were comprised of 20% intradermal melanocytic nevus, 11.3% epidermal cyst, 7.6% dermoid cyst, 10% seborrheic keratosis, 6.3% xanthelasma, 2.5% wart, 3.8% compound nevus, 5% fibroconnective tissue, 3.8% squamous papilloma, 3.8% neurofibroma, 2.5% comedone,2.5% apocrine hidrocystoma, 2.5% foreign body type granuloma, and 1.3% of others (arteriovenous hemangioma, cavernous hemangioma, cutaneous horn, etc.) The premalignant lesions were 2 cases of actinic keratosis. Benign lesions had an equal frequency of occurrence in the upper and lower lids. Malignant lesions were seen more in the lower lid. Premalignant lesions were seen in the lower lid. The mean age at diagnosis was 45.8 ± 23.06 years for patients with benign lesions and 63.5 ± 16.7 years for patients with malignant lesions. The mean age for patients with premalignant lesions was 81.5 ± 9.19 years (P &lt; 0.001). Conclusions: In our study, benign lesions were seen predominantly in young persons and malignant lesions were mostly seen in elderly persons. There is an equal occurrence of malignant lesions in males and females, and recurrence after excision was infrequent.

Evaluation and management of benign tumors of the eye and eyelid

Benign tumors of the eye and eyelid are common in children and adults, and they rarely undergo malignant transformation. Their workup and management have evolved over the years with increasing advancements in surgical and laser therapies. This contribution focuses on describing the following benign eye and eyelid tumors and their diagnostic and treatment approaches: congenital and acquired melanocytic nevi; nevus of Ota (Hori nevus); conjunctival papilloma; seborrheic keratosis; epidermoid cyst; dermoid cyst; milium; xanthelasma; hemangioma (cherry angioma and pyogenic granuloma); neurofibroma; neurilemmoma (schwannoma); and fibroepithelial polyp. Surgical removal is the primary treatment approach for many of these benign tumors. With advancements in laser technologies, there are now several laser types that can be used in the treatment of these benign eye and eyelid tumors. Other treatment modalities include cryosurgery, electrosurgery, and topical or intralesional medications. We hope this review will provide a reference to dermatologists and ophthalmologists in their approach to evaluation and management of benign eye and eyelid tumors.

Chalazion-mimicked eyelid angiosarcoma in a young Asian with good prognosis: a case report

BackgroundAngiosarcoma is an extremely rare malignant tumor. So far, only about 42 cases of angiosarcoma involving the eyelids have been reported. Eyelid angiosarcoma occurs more frequently in elderly Caucasian males and is prone to misdiagnosis. We present a case report in a young Asian male patient with eyelid angiosarcoma that was misdiagnosed as a chalazion.Case presentationA 46-year-old South Korean male with no underlying disease had a right lower lid mass. The lesion was initially misdiagnosed as a chalazion at a local clinic, but a diagnosis of eyelid angiosarcoma was made after the first biopsy trial. PET-CT was performed to ensure that there was no metastasis in the whole body. Surgical excision with enough surgical margin was used alone for treatment and reconstruction was performed with a tarsoconjunctival advancement flap (modified Hughes procedure), which helped ensure good cosmesis. No recurrence was observed 4 years and 5 months after the surgery.ConclusionsThe current study presents the first case of chalazion-mimicked eyelid angiosarcoma in a young Asian male aged under 50 years. This case shows that even if a benign eyelid disease is suspected in a young patient, an incisional biopsy must be performed to confirm whether the lesion is malignant. Since the prognosis is good for the case of eyelid angiosarcoma, if there is no clear evidence of distal metastasis, surgical resection should be performed with an enough safety margin.

Разработка нового нанобиотехнологического метода и его применение для дифференциальной диагностики опухолей придаточного аппарата глаза

Aim: to develop a new nanobiotechnology method for the differential diagnosis of ocular adnexal tumors. Patients and Methods: 192 eyelid or conjunctival tumor samples from 192 patients were examined. Controls were healthy tissue samples from the same eye. To register and obtain significant differences in the generation of biogenic silver nanoparticles in situ, the key parameters of the reaction of the reduction of silver cations were selected and optimized. To generate de novo biogenic silver nanoparticles, tissue samples were placed in a sterile solution of a cation source in aseptic conditions. Nanoparticles were generated in situ using a sterile solution of Tollens' reagent (Ag(HN3)2NO3). Results: the optimal parameters of a new nanobiotechnology method were established to conduct the reduction reaction to generate biogenic silver nanoparticles. The required concentration of Tollens' reagent (source of cations) was 63 μg/ml. The wavelength used to observe the de novo generation of biogenic silver nanoparticles (λ) was 410 nm. Obtaining the most significant changes in the optical density of the reaction mixture with biogenic nanoparticles required 10 to 20 min, although the first changes were documented starting from the 5th minute of the reduction reaction. Benign and malignant tumors are characterized by different metabolic activities, i.e., benign eyelid and conjunctival tumors reduce cations more slowly than malignant tumors. The parameters of reducibility of benign ocular adnexal tumors did not significantly differ depending on tumor location and type. Among the malignant conjunctival tumors, melanoma is characterized by the highest reducibility p&lt;0.05). Among the malignant eyelid tumors, no significant differences were found for different tumor types. Conclusions: this novel nanobiotechnology method provides a differential diagnosis of benign and malignant ocular adnexal tumors. The practical relevance of this method lies in differentiating benign and malignant tumors to schedule management strategies and surgical interventions. KEYWORDS: tumor, eyelids, conjunctiva, silver nanoparticles, biogenic synthesis, express diagnostics, ocular oncology. FOR CITATION: Saakyan S.V., Skladnev D.A., Alekseeva A.P., Beznos O.V., Sorokin V.V. Development of a new nanobiotechnology method for the differential diagnosis of ocular adnexal tumors. Russian Journal of Clinical Ophthalmology. 2024;24(1):25–29 (in Russ.). DOI: 10.32364/2311-7729-2024-24-1-5.

Diagnosis and treatment of malignant eyelid tumors.

Malignant tumors of the eyelid are much less frequent than benign eyelid alterations. These are frequently incidental findings without symptoms which are often overlooked or misinterpreted by patients. This article gives an overview of clinical aspects, diagnostics and treatment of the five most common malignant eyelid tumors and exemplarily explains the essential principles of evidence-based treatment of malignant eyelid tumors. This narrative review was prepared based on aselective literature search. The depiction of the treatment of eyelid tumors is supported by illustrations of clinical cases. The medical history and inspection provide initial indications of malignancy. Every eyelid change suspected of being malignant should be examined histologically to confirm adiagnosis. By far the most common malignant eyelid tumor in Europe is basal cell carcinoma, which metastasizes only in exceptional cases. Squamous cell carcinomas, sebaceous adenocarcinomas, melanomas and Merkel cell carcinomas occur much less frequently. In these cases, potential metastasis in particular must be considered when making the diagnosis and staging has to be initiated. Surgical excision into healthy tissue with tumor-free margins is the gold standard for malignant eyelid tumors. Non-surgical adjuvant or neoadjuvant forms of evidence-based treatment can be initiated based on the individual case to minimize the risk of recurrence and metastasis. It is essential to recognize eyelid changes at an early stage, to classify them correctly and to initiate the appropriate treatment. The interaction between the general condition and the personal needs of apatient as well as state of the art medicine are the keys to a good personalized treatment.

Comparison of the clinical characteristics of benign and malignant eyelid lesions: an analysis of 1423 eyelid lesions, compared between ophthalmology department and plastics department.

Oculoplastic surgeons excise and reconstruct eyelid tumors, although plastic surgeons have traditionally managed these cases. Current demand of this surgery is growing, and planning referral services is a health management necessity. This pilot study retrospectively reviewed same population eyelid specimens excised by both disciplines comparing data. Clinical and epidemiologic features of 1423 eyelid lesions biopsied between 2015- 2020 in Emek Medical Center (EMC), Israel were reviewed. Among 1423 specimens, 1210 (85.0%) were benign and 213 (15.0%) were malignant/pre-malignant. Mean age at diagnosis was significantly higher in malignant tumors than in benign tumors (76 and 59years respectively, p value < 0.001). The most common benign eyelid lesions were soft fibroma (20.1%), seborrheic keratosis (11.0%) and melanocytic nevus (10.3%). The most common malignant/pre-malignant eyelid tumors were basal cell carcinoma (BCC) (9.2%), actinic keratosis (2.6%) and Bowen's disease (1.9%). Ophthalmology removed 37 malignant/pre-malignant lesions (5.4%) out of 683 compared to plastics removing 142 malignant/pre-malignant lesions out of 740 (19.2%) specimens. Eyelid malignancy in the plastics department was significantly higher than in the ophthalmology department (p value < 0.001). 270 (70.0%) lesions caused by UV exposure were removed by plastics and 116 (30.0%) were removed by ophthalmology (p value < 0.001). Eyelid lesions in patients aged 76 or older are more likely to be malignant. Ophthalmology eyelid specimens in younger patients are more commonly benign and related to inflammation. Specimens from the plastics department are more commonly malignant, related to UV-exposure, and are from older patients. This difference may be due to a misconception that plastic surgeons have more eyelid cancer reconstruction experience than oculoplastic surgeons, or less awareness of the oculoplastic expertise available today.

Differential diagnoses of benign eyelid tumors in children and adolescents

The clinical diagnosis as well as the treatment approach of periocular tumors in childhood and adolescence can be challenging. Knowledge of the most important differential diagnoses and their clinicopathological correlation is helpful for the treatment approach. The clinical and histological characteristics of various eyelid tumors in childhood and adolescence are presented taking the excision frequencies into consideration. The frequencies and clinicopathologic correlation of the most important eyelid tumors (n = 485) are presented based on the data of the ophthalmopathology laboratory of the University Eye Hospital Bonn from 1998-2023. The most frequent tumor in childhood and adolescence is chalazion (57.3%), followed by dermoid cysts (16.7%) and molluscum contagiosum (9.6%). Other lesions of childhood and adolescence include pilomatrixoma (2.1%), hemangioma and other vascular malformations (4.7%) and rare differential diagnoses, such as subcutaneous calcifying nodules and xanthogranuloma. Guidance on the approach in different age groups is presented in the form of adecision tree. Tumors in children and adolescents are mostly benign, yet there are important indications for excision. A histological examination of any excised tissue in childhood and adolescence is obligatory because unexpected findings are not uncommon and the spectrum of lesions also differs from that in adulthood. Knowledge of the histological picture can be very helpful in the preoperative clinical classification and for planning further procedures.

Differentiating malignant and benign eyelid lesions using deep learning

Artificial intelligence as a screening tool for eyelid lesions will be helpful for early diagnosis of eyelid malignancies and proper decision-making. This study aimed to evaluate the performance of a deep learning model in differentiating eyelid lesions using clinical eyelid photographs in comparison with human ophthalmologists. We included 4954 photographs from 928 patients in this retrospective cross-sectional study. Images were classified into three categories: malignant lesion, benign lesion, and no lesion. Two pre-trained convolutional neural network (CNN) models, DenseNet-161 and EfficientNetV2-M architectures, were fine-tuned to classify images into three or two (malignant versus benign) categories. For a ternary classification, the mean diagnostic accuracies of the CNNs were 82.1% and 83.0% using DenseNet-161 and EfficientNetV2-M, respectively, which were inferior to those of the nine clinicians (87.0–89.5%). For the binary classification, the mean accuracies were 87.5% and 92.5% using DenseNet-161 and EfficientNetV2-M models, which was similar to that of the clinicians (85.8–90.0%). The mean AUC of the two CNN models was 0.908 and 0.950, respectively. Gradient-weighted class activation map successfully highlighted the eyelid tumors on clinical photographs. Deep learning models showed a promising performance in discriminating malignant versus benign eyelid lesions on clinical photographs, reaching the level of human observers.

Retrospective demographic analysis of 450 eyelid tumours

Eyelids are a small anatomical structure, yet they contain several histological layers from which benign and malignant tumours can originate. Compared to other parts of the face, the eyelids are often the first place where neoplasms or disease changes are noticed. The aim of this study was to analyze eyelid tumours over a 10-year period. A retrospective study of 436 patients (450 eyes) who underwent oculoplastic surgery in an ophthalmology department over a 10-year period was performed. Descriptive, dispersion and correlation analyses were performed. The demographic analysis provided a clear assessment of the distribution and incidence of eyelid tumours according to age, size, histology and place of residence. Age and malignancy were in a positively significant relationship and increased together. The cases of benign eyelid tumours began to increase in terms of number out of the total cases observed after the age of 40, and malignant tumours after the age of 60. The trend in benign tumours continued until the age of 70, when the increase became four-fold, after which they decreased again at the expense of malignant tumours, which were already increased six-fold by the age of 70. Eighty percent of all malignant tumours of the eyelids were diagnosed after 60 years of age. A patient with an eyelid tumour is to be referred for treatment to an ophthalmologist by medical specialists of all specialties. Early patient referral is directly related to treatment success.

Diagnosis and treatment of benign eyelid tumors

Benign tumors of the eyelids are frequent entities. They are often cause for cosmetic concern or can lead to irritation of the ocular surface. The differentiation from premalignant or malignant eyelid tumors is particularly important. In most cases this can be done clinically; however, in some cases histological evaluation is warranted. The aim of this article is to characterize the most important benign tumors of the eyelid and to ascertain when a histological examination is necessary. Furthermore, fundamental treatment procedures are discussed. This narrative review was prepared based on aselective literature search. The characteristics of some eyelid tumors are underlined with illustrations from clinical cases. Most benign eyelid tumors are treated because of cosmetic or functional concerns. Some of them, including actinic keratosis, keratoacanthoma, cutaneous horn, trichofolliculoma, resemble malignant lid tumors or precancerous lesions and are thus excised in oder to obtain a diagnosis. Dermoid cysts can cause complications and congenital melanocytic naevi can exhibit malignant transformation and may need treatment. Inflammatory tumors can be treated conservatively in most cases but might require surgery in certain cases. Systemic associations exist with some of the benign lid tumors and should not be overlooked as they can be crucial for overall patient morbidity. Benign tumors of the eyelids are frequent and can be found at any age depending on the diagnosis. This article describes the lesions most commonly encountered in the clinical routine and helps at making a plan for further management.

Diagnosis and treatment of malignant eyelid tumors

Malignant tumors of the eyelid are much less frequent than benign eyelid alterations. These are frequently incidental findings without symptoms which are often overlooked or misinterpreted by patients. This article gives an overview of clinical aspects, diagnostics and treatment of the five most common malignant eyelid tumors and exemplarily explains the essential principles of evidence-based treatment of malignant eyelid tumors. This narrative review was prepared based on aselective literature search. The depiction of the treatment of eyelid tumors is supported by illustrations of clinical cases. The medical history and inspection provide initial indications of malignancy. Every eyelid change suspected of being malignant should be examined histologically to confirm adiagnosis. By far the most common malignant eyelid tumor in Europe is basal cell carcinoma, which metastasizes only in exceptional cases. Squamous cell carcinomas, sebaceous adenocarcinomas, melanomas and Merkel cell carcinomas occur much less frequently. In these cases, potential metastasis in particular must be considered when making the diagnosis and staging has to be initiated. Surgical excision into healthy tissue with tumor-free margins is the gold standard for malignant eyelid tumors. Non-surgical adjuvant or neoadjuvant forms of evidence-based treatment can be initiated based on the individual case to minimize the risk of recurrence and metastasis. It is essential to recognize eyelid changes at an early stage, to classify them correctly and to initiate the appropriate treatment. The interaction between the general condition and the personal needs of apatient as well as state of the art medicine are the keys to a good personalized treatment.

CLINICAL STUDY OF BENIGN CYSTIC EYELID TUMORS

Aims And Objectives: To study the incidence of benign cystic eyelid tumors. Results: It was observed in our study that benign cystic tumors are most common in the age group of 30-45 yrs,in male patients, meibomian cyst are the common tumors.

Clinical Signs for Differential Diagnosis of Eyelid Tumours.

This article aims to present the differential diagnostics of benign and malignant eyelid tumours. The most common malignant eyelid tumour is basal cell carcinoma, followed by squamous cell carcinoma. The common signs of malignity are loss of lashes, ulceration, and infiltration of the lesion. Often the clinical appearance is various and therefore only a histological analysis gives the proper diagnosis. For most tumours, surgical resection is the gold standard of therapy. The reconstruction of the defects should be performed by an experienced oculoplastic surgeon. In malignant tumours that require large safety margins, the defect can be easily very large, and the reconstruction must then be performed with advanced ophthalmic plastic reconstruction techniques.

Pathological Outcomes of Eyelid Tumors Running title: Eyelid Tumors

Objectives: To evaluate and compare the pathological outcomes, demographic and clinical features of benign and malignant tumors of the eyelid. Methods: The records of patients who were operated on for eyelid tumors in the oculoplastic surgery unit of our clinic were retrospectively reviewed. The age and sex of the patient, the location and laterality of the tumor, the histopathological diagnosis of the lesion, and whether it was benign or malignant were recorded. Results: A total of 251 patients who were operated on for eyelid tumors and underwent histopathological examination were included in the study. Histopathological results showed benign eyelid tumors in 230 patients (91.6%) and malignant eyelid tumors in 21 patients (8.4%). The age of the patients in the malignant eyelid tumors group was significantly higher than in the benign eyelid tumors group (p&lt;0.001). The localization rate on the right side was significantly higher in malignant eyelid tumors compared to benign eyelid tumors (p=0.003). The lower eyelid localization rate was significantly higher in malignant eyelid tumors than benign eyelid tumors (p&lt;0.001). Conclusion: Although the majority of eyelid tumors are benign, the pathological results of the patients are extremely important so that malignant masses that appear benign are not overlooked. It should be kept in mind that these tumors have a high probability of malignancy, especially in advanced age and lower eyelid locations, and may lead to serious morbidity if treated late.

DEMOGRAPHIC PROFILE AND FREQUENCY OF EYELID AND CONJUNCTIVAL TUMORS; A NORTH INDIAN PERSPECTIVE.

Background: Eyelid and conjunctival tumors are the most common tumors that are encountered by an ophthalmologist. There are innumerable benign and malignant tumors of eyelids and conjunctiva owing to their histological structure. Proper diagnosis both clinically and on histopathological examination helps in appropriate management in cases of both benign and malignant lesions. The purpose of this study was to assess the demographic prole and frequency of eyelid and conjunctival tumors in patients presenting in our OPD. Materials And Methods: A total of 78 patients attending our Eye OPD presenting with eyelid or conjunctival tumors were admitted in hospital and underwent surgical management or excision biopsy and specimens were sent for histopathological examination. The purpose was to study the demographic prole and frequency of benign and malignant eyelid and conjunctival tumors in patients presenting in our hospital. Results: Out of 78 patients, 42(53.84%) were cases of eyelid tumors and 36(46.15%) were of conjunctival growths. Mean age of presentation in cases of eyelid tumors was 54(range 3-75) years and conjunctival tumors was 40(range 8-68) years. Benign lesions were more common than malignant in both eyelids and conjunctiva. Females were affected more than males. Conclusion: In our study, we observed that most frequently observed eyelid and conjunctival growths were benign. Mostly growths were seen in females and study population was largely from rural areas who had cosmetic issues or visual disturbances as main complaints.

Modified argon laser therapy for benign tumor of the eyelid

BackgroundTo report about the therapy of benign eyelid tumors with a modified argon laser technique as an alternative to surgery.MethodsNineteen benign tumors of the eyelid were included in this study. After staining the surface of the tumor with a violet marker, low-energy argon laser photoablation was performed. A mean number of 312 spots (spot size ranging from 150 to 500 μm) with a power of 200 to 400 mW, and a duration between 0.1 and 0.2 s were applied.ResultsThe eyelid tumors were located mainly in the lower eyelid (58%). Dermal nevi and papilloma were the most frequently treated lesions. Over a mean follow-up period of 10.5 months (range 6–18 months), all eyelid tumors were successfully treated by a single session of laser therapy. All patients were satisfied with the laser therapy and the cosmetic result. No postoperative complications were observed. No relapses occurred during follow-up.ConclusionsOur modified method of argon laser therapy utilizes the staining of the surface of the eyelid tumor to increase the amount of thermal laser energy absorbed by the target. This novel technique is simple and effective for treating benign eyelid tumors.